Nyxoah Reports Revenue of 10 Million Euros in 2025
Belgian medical technology company Nyxoah has released its unaudited preliminary results for the fiscal year 2025, marked by its first full quarter of commercialization in the United States following FDA approval.
Global Revenue Exceeds Expectations
According to the press release dated January 12, 2026, Nyxoah recorded a global revenue exceeding 10 million euros for the entire fiscal year 2025. This performance is based on the launch of its Genio system in the American market and the continuation of its international geographical expansion. The company indicates that the fourth quarter of 2025 was its first full quarter of commercialization in the United States following the FDA approval. The company specifies that these preliminary results are unaudited and subject to revisions until the publication of its complete financial results in its annual report on Form 20-F.
Revenue Forecasts for Early 2026
The company has communicated revenue forecasts for the first quarter of 2026, however, it did not specify the amounts in the press release. Nyxoah mentions having a waiting list for additional surgeon training and for patients scheduled for implants. The group reports initial results obtained by its American patients, without providing numerical data on this matter. The estimates concerning revenue, cash, cash equivalents, and financial assets presented remain preliminary, the company clarifies.
Participation in the 44th Annual J.P. Morgan Healthcare Conference
Nyxoah will participate in the 44th annual J.P. Morgan Healthcare Conference on Thursday, January 15, 2026, according to the press release. The company plans to make a presentation at 12:00 PM Pacific Time, accessible via webcast on the Investor Relations page of its website. The Belgian company, listed on Euronext Brussels and on the Nasdaq, develops and markets the Genio system, a hypoglossal nerve neurostimulation therapy designed to treat obstructive sleep apnea. The system received CE marking in 2019 and FDA approval in August 2025 for a subgroup of adult patients with moderate to severe obstructive sleep apnea.
